Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Feb;87(2):177-84.
doi: 10.1136/heart.87.2.177.

Cardiac transplantation

Mario C Deng  1
Affiliations
Review

Cardiac transplantation

Mario C Deng. Heart. 2002 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The alloimmune response consists of antigen (Allo Ag) presentation in the context of major histocompatibility (MHC) molecules either by donor cells or by recipient cells to the recipient's T cells via T cell receptor (TCR). This leads to T lymphocyte differentiation to CD4 T cells of T helper1 (Th1) or T helper2 (Th2) phenotype, CD8 cytotoxic T cells (Tc), and B lymphocyte development into plasma cells producing specific clones of antibodies. These immunocompetent cells destroy the allogeneic graft cells. In addition, an inflammatory response by the innate immune system involving macrophages (Mph) participates in this networked alloimmune response. Cytokines (IL2-10, TNF, IFng) play an important role in this orchestrated response. The Th2 subset may favour graft acceptance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: Eighteenth official report – 2000. J Heart Lung Transplant 2001;20:805–15. - PubMed
    1. Packer M, Coats AJ, Fowler MB, et al for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–8. ▸ First demonstration of survival benefit by β blockers in an advanced heart failure population considered elective cardiac transplantation candidates. - PubMed
    1. Rose EA, Gelijns AC, Moskowitz AJ, et al. for the REMATCH Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435–43. ▸ First study to test in a randomised design the survival benefit of mechanical circulatory support in advanced heart failure patients. - PubMed
    1. Hunt SA. 24th Bethesda conference: cardiac transplantation. J Am Coll Cardiol 1993;22 (suppl 1):1–64. - PubMed
    1. Deng MC, De Meester JMJ, Smits JMA, et al, on behalf of COCPIT Study Group. The effect of receiving a heart transplant: analysis of a national cohort entered onto a waiting list, stratified by heart failure severity. BMJ 2000;321:540–5. ▸ First national cohort study to suggest that survival benefit of cardiac transplantation is restricted to patients at highest risk of dying from heart failure. - PMC - PubMed